Overview
Yin Li practices practicing medicine in Guangzhou, China.
Her clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Squamous Cell Lung Carcinoma, and Acute Lymphoblastic Leukemia (ALL).
She is actively involved in clinical research, co-authoring 14 peer reviewed articles.
Gender
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Yin Li
Is Yin Li a top-rated expert for Acute Myeloid Leukemia (AML)?
MediFind is an objective health platform that identifies experts based on real-world data. Yin Li is classified as an Experienced expert for Acute Myeloid Leukemia (AML), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Yin Li participate in research or clinical trials?
Yes. Yin Li has published 14 articles and abstracts on conditions like Acute Myeloid Leukemia (AML). You can view a list of Yin Li's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- Acute Lymphoblastic Leukemia (ALL)
- Acute Myeloid Leukemia (AML)Ms. Li isExperienced. Learn about Acute Myeloid Leukemia (AML).
- LeukemiaMs. Li isExperienced. Learn about Leukemia.
- Squamous Cell Lung CarcinomaMs. Li isExperienced. Learn about Squamous Cell Lung Carcinoma.